In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 5, 1998, Pages 385-390

  Romanelli, Simona ^a   Perego, Paola ^a   Pratesi, Graziella ^a   Carenini, Nives ^a   Tortoreto, Monica ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cisplatin; Ovarian cancer; Topotecan

Indexed keywords

CISPLATIN; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG INTERACTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031905299     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050755     Document Type: Article

References (22)

1. Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35
2. Benard JB, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, Riou G (1985) Characterization of a human ovarian adenocarcinoma line, IGROV-1, in tissue culture and in nude mice. Cancer Res 45: 4970
3. Boothman DA, Fukunaga N, Wang M (1994) Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res 54: 4618
4. Caserini C, Pratesi G, Tortoreto M, Bedogne B, Carenini N, Supino R, Perego P, Zunino F (1997) Apoptosis as determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin Cancer Res 3: 955
5. Cheng MF, Chatterjee S, Berger NA (1994) Schedule-dependent cytotoxicity of topotecan alone und in combination chemotherapy regimens. Oncol Res 6: 269
6. Davis LG, Dibner MD, Battey JF (1988) Basic methods in molecular biology. Elsevier/North Holland, Amsterdam
7. Eastman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730
8. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171
9. Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y (1996) Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 2: 687
10. Kaufmann SH, Peereboom D, Buckwatter CA, Svingen PA, Grochan LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734
11. Kern DH, Morgan CR, Hildebrand-Zanki SU (1988) In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 48: 117
12. Kondo Y, Kuo SM, Watkins SC, Lazo JS (1995) Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55: 474
13. Marchesini R, Colombo A, Caserini C, Perego P, Supino R, Capranico G, Tronconi M, Zunino F (1996) Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer 66: 342
14. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215
15. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR (1996) cis-Diamminedichloroplatinum(II) induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37: 463
16. Ozols RF, Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: 222
17. Perego P, Casati G, Gambetta RA, Soranzo C, Zunino F (1993) Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells. Cancer Lett 72: 53
18. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556
19. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689
20. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647
21. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC (1996) Sequences of topotecan and cisplatin: phase I, pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 14: 3074
22. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271